account adjust acquisition-rel cost certain
signific item
forecast remainco compound sale ep respect
newco project see revenu declin temper ep eros
time keytruda estim contribut remainco sale ep
higher peer relianc one drug given enhanc risk reiter
market perform rate share
result announc would separ compani two part
effect innov portion repres total sale
includ oncolog anti-infectives/hospit januvia product newco sale
estim includ women biosimilar zetia/vytorin
diversifi brand provid high-level detail attach model attempt
dissect two part
compound newco ep declin
rais total ep estim year amount rang
ep estim vs previous guidanc
consensu vs previous
consensu chang impli ep compound-annual-growth-rate
vs last-publish remainco ep forecast
assum compani separ
impli ep compound-annual-growth-rate newco ep forecast
impli ep declin
howev believ newco recov grow time keytruda
project contribut remainco ep
modest chang sale build-up lower
rais forecast total sale compound
remainco gener sale growth newco sale declin
time remainco sale forecast total
newco sale project total declin keytruda
project contribut remainco sale rise vs
respect total comparison opdivo forecast contribut
sale trulic sale duplix sni sale humira
contribut sale
total basi forecast oper margin
higher last-publish model
pleas see page report import disclosur
merck competit posit line lung cancer clear posit merck face
uncertainti includ januvia outlook competit market competit pressur
isentress zostavax thin pipelin spin newco enhanc risk given even
greater relianc keytruda believ risk balanc opportun therefor remain
market perform stock
keytruda data readout tnbc bladder
keytruda approv cscc pdufa
dose pdufa
lynparza approv ovarian
mainten cancer mcrpc
oper margin improv
expect
new product unabl off-set declin
januvia zostavax isentress
merck global health care compani includ prescript medicin vaccin
biolog therapi anim health strong product presenc oncolog
cardiovascular anti-infect anti-inflammatori diabet area among other
anim health divis focus mainli feed anim merck spin newco consist
women biosimilar zetia/vytorin diversifi brand
cowen compani
cgr antibodi approv tumor type mani tumor types/combin qd antidiabet patent exp pedi exclus could add month crohn uc ra pa earli ra psoriasi patent expir biosimilar exposur marketsoth newer bridion simponi zerbaxa belsomra steglatro vax adempa belsomra gefapix criticaloth anti-infect oncologyanim mainli feed anim ou bravecto success flea/tick companion anim spin/split/sal tap merck remainco ezetimib gener vytorin gener modest growth thru newco women biosimilar diversfi brandstot ep versu industri averag ep cowen
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
 riociguat solubl guanyl cyclas sgc modul approv eu pah cteph japan phase heart failur victoria ref-hf primari endpoint met part bayer nrx share patent expir pedi exclus could add monthsjanuvia patient expir exclus could add month januvia qd antidiabet competit threat given proven cv ertugliflozin diabet inhib w/pfe app mono combo w/sitagliptin metformin omarigliptin diabet qweek inhibitor market japan file plan diabet phase ii clinic holdtot market bridion market eu japan eu patent exp sugammadex anesthesia revers suvorex insomnia orexin neuropeptid approv us japan yet file eu schizophrenia phase iitot golimumab ra pa uc approv eu canada competit clip growthremicad crohn uc ra pa earli ra psoriasi patent expir biosimilar exposur marketstot ph chronic acut cough includ idiopath pulmonari fibrosi sleep apnea migrain endometriosi ph iitot cowen
compani data cowen compani estim
 qd market blunt erosionisentress qd approv eu hiv integras inhibitor treatment resist nave approv gilead gsk tivicay pose competitionnoxafil patent expir eu patent expir posaconazol oral antifung approv prophylaxi oral candidiasi cubicin advers court decis allow gener first gener teva launch sale nv modest royaltiescubicin cubist acquir roch pegasys/copegu pressur new drug clip durat therapyintron support use oncolog applicationsribavirin/rebetol older modalityintron substanc patent exp formul patent exp settlement allow gener launch aug ou patent expiredcancida antifung qd iv new indic price share eros due competitioninvanz patent expir compound composit gener launch broad spectrum carbapenem oral im iv qdprimaxin emerg market-drivenprimaxin bolster sale effort blunt eros patent expir launch competit landscap pressureszepati launch eu japan competit landscap pressureszepati hepat grazoprevir proteas inhibitor elbasvir competit landscap ceftolozane/tazobactam ww right ex asia-pacif gram neg infect habp/vabp apprv difficil bezlotoxumab tx difficil associ diarrhea cdad approv medarex/ma biolog labspifeltro mono /delstrigo doravirin nnrti hiv qd dose approv letermovir cmv prophylaxi transplant patient roll-out tedizolid gram po infect launch phase habp/vabp hiv infect phase relebactam imipenem/cilastatin cuti/ciai approv older antibioticstot cowen
compani data cowen compani estim
 approv tumor type includ melanoma lung renal chl bladder msi-hkeytruda eu approv melanoma lung chl bladder gastric nkeytruda antibodi mani tumor type melanoma phase solid tumor phase rcc phase saha cutan t-cell lymphoma roll-out underway clinic trial underwayemend aprepit substanc antagonist emesi patent exp oral iv franchis oral/ivtemodar teva launch gener gener japan pat exp eu temodar chemotherapeut aa gbmazn lynparza/selumetinib record sale net cog sg record lineeisai lenvima record sale net cog sg record linetot cowen
compani data cowen compani estim
 competit gsk shingrix prompt zostavax declin sale reflect dissolut spmsd jv ad herp zoster vaccin adult year singl sq dose plu booster investigatedproquad mmr ii varivax mmr ii varivax sale reflect dissolut spmsd jv ad mmr ii varivax support health initi demand buy patternsrotateq sale reflect dissolut spmsd jv ad rotaviru vaccin oral liquid good safeti profil market ww competit gskgardasil/gardasil approv year old femal male sale gardasil two dose approv fda/cdcgardasil/gardasil sale reflect dissolut spmsd jv ad approv two dose regimen china launch boostsgardasil/gardasil hpv vaccin borrow cdc stockpil refil hexaval combin pediatr vaccin approv eu pneumoconjug vaccin phase valent tough competit ebola vaccin approv cytomegaloviru vaccin phase respiratori syncyti viru rsv phase iipneumovax use dose post prevnar boost tie birth cohortpneumovax support integr spmsd jv marketspneumovax pneumococc vaccin adultstot total cowen
compani data cowen compani estim
healthlivestock leader vaccinescompanion anim bravecto oral approv may key driver line extens launchinganim boost smaller acquisit antelliq cattl monitor close anim bravecto numer therapeut productsanim line estim anim market growth remainco total sale cowen
compani data cowen compani estim
 zetia lipitor market eu market cozaar/hyzaar arb hypertens gener competitionzetia patent expir glenmark enter month exclusivityzetia patent expir gener launch ezetimibevytorin exclus laps patent expir lost patent case euvytorin ezetimibe/simvastatin improve-it achiev endpoint garner fda labelintegrilin revenu repurchas milleniumzocor cholesterol reduct patent expir develop patent expir littl eros japan despit patent lapsetot antidepress patent expir januari major sale ex-u maxalt/maxalt mlt patent expir maxalt/maxalt mlt patent expir eumaxalt/maxalt mlt agonist anesthesia patent expir approv market countriestot cowen
compani data cowen compani estim
implanon/nexplanon patent expir patent expir implant contracept patent expir juli progesteron/estrogen market eu exclus pursu corifollitropin alpha infertil market eu exclus pursu nuvar patent expir april first gener launch contracept vagin contracept patent expir septemb aq aq aq follitropin beta inject patent expir june oral contracept patent expir decemb contracept patent expir septemb oral contracept patent expir march contraception/women cowen
compani data cowen compani estim
 gener launch over-the-counter product also pressurenasonex gener eu allerg rhinitisdulera asthma market copd longer pursu dulera launch copd four market asthma market dulera mometasone/formoterol ics/laba twice daili competit pressuressingulair patent expir patent expir eu includ month pedi exclus japansingulair asthma/allergyasmanex market asmanex market countriesasmanex asthma dri powder qd inhal corticosteroid patent devic formul expir beta agonist asthma cfc hfa completeclarinex small market retainedclarinex claritin rx/otc sold bayer ag tax part consum transact close claritin/clarinex older product europetot cowen
compani data cowen compani estim
 psoriasi moder potenc steroid patent exp compound cream lotion bph gener competit fosamax osteoporosi gener launch patent expir bald domin small acceler time upper lower gi recoveri post surgeri cubistbiosimilars/oth renflexi infliximab brenzi etanercept biosimilar total newco total sale sale guidanc includ fx impact cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl januvia vytorin
zetia isentress success pipelin product especi suvorex odanacatib
anacetrapib lambrolizumab success deal patent litig patent
expir pressur binari risk includ safeti issu involv odanacatib
improve-it studi vytorin
